Phase 3 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to understand the study and are willing to sign a written consent form.
- People aged 18 to 80 years old.
- People whose general physical health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system (confirm with trial site).
- People who have been diagnosed with pancreatic cancer that has spread to other parts of the body, confirmed through a tissue or cell sample.
- People whose cancer has continued to grow or spread after two previous rounds of treatment.
- People whose blood test results show their organs are functioning at an adequate level.
- People who have at least one area of cancer that can be measured on a scan, according to standard medical guidelines.
- People whose expected survival is at least one month.
- Women who could become pregnant, and men, who agree to use reliable contraception throughout the study.
Who may not be able to join:
- People whose tissue sample confirmed a type of pancreatic cancer other than adenocarcinoma.
- People who have inflammation in their digestive system, such as pancreatitis, cholecystitis, or cholangitis.
- People who are pregnant or currently breastfeeding.
- People who have a condition called G6PD deficiency, which affects how the body processes certain substances.
- People with severe or uncontrolled health conditions that could affect their ability to follow the study plan or make results harder to interpret.
- People with kidney failure or who are currently on dialysis.
- People with other serious health conditions that, in the treating doctor's opinion, could significantly affect their safety during treatment.
- People who are unwilling or unable to follow the study procedures.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Guopei Luo, MD, Shanghai Cancer Center
Phone: 86 21 64031446
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Quality of life (QOL) questionnaire
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.